Roche is betting a new type of cancer immunotherapy could help to improve on the benefit offered by the first generation of immune-boosting drugs.
https://www.biopharmadive.com/news/roche-first-tigit-data-asco-tiragolumab/577897/
Roche is betting a new type of cancer immunotherapy could help to improve on the benefit offered by the first generation of immune-boosting drugs.
https://www.biopharmadive.com/news/roche-first-tigit-data-asco-tiragolumab/577897/